MAPT and Alzheimer disease: While this framework acknowledges the conviction shared by many in the field that amyloid-β drives the pathogenesis of AD, with pathological tau occurring as a secondary event, proximate to neurodegeneration and cognitive decline (Fig. 6), it also states that the other pathological sequences may be possible.